PortalPublikationenIn vivo imaging of microenvironmental and anti-PD-L1-mediate...

In vivo imaging of microenvironmental and anti-PD-L1-mediated dynamics in cancer using S100A8/S100A9 as an imaging biomarker

Standard

In vivo imaging of microenvironmental and anti-PD-L1-mediated dynamics in cancer using S100A8/S100A9 as an imaging biomarker. / Helfen, Anne; Rieß, Jan; Fehler, Olesja; Stölting, Miriam; An, Zhengwen; Kocman, Vanessa; Schnepel, Annika; Geyer, Christiane; Gerwing, Mirjam; Masthoff, Max; Vogl, Thomas; Höltke, Carsten; Roth, Johannes; Ng, Tony; Wildgruber, Moritz; Eisenblätter, Michel.

in: NEOPLASIA, Jahrgang 28, 100792, 06.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Helfen, A, Rieß, J, Fehler, O, Stölting, M, An, Z, Kocman, V, Schnepel, A, Geyer, C, Gerwing, M, Masthoff, M, Vogl, T, Höltke, C, Roth, J, Ng, T, Wildgruber, M & Eisenblätter, M 2022, 'In vivo imaging of microenvironmental and anti-PD-L1-mediated dynamics in cancer using S100A8/S100A9 as an imaging biomarker', NEOPLASIA, Jg. 28, 100792. https://doi.org/10.1016/j.neo.2022.100792

APA

Helfen, A., Rieß, J., Fehler, O., Stölting, M., An, Z., Kocman, V., Schnepel, A., Geyer, C., Gerwing, M., Masthoff, M., Vogl, T., Höltke, C., Roth, J., Ng, T., Wildgruber, M., & Eisenblätter, M. (2022). In vivo imaging of microenvironmental and anti-PD-L1-mediated dynamics in cancer using S100A8/S100A9 as an imaging biomarker. NEOPLASIA, 28, [100792]. https://doi.org/10.1016/j.neo.2022.100792

Vancouver

Helfen A, Rieß J, Fehler O, Stölting M, An Z, Kocman V et al. In vivo imaging of microenvironmental and anti-PD-L1-mediated dynamics in cancer using S100A8/S100A9 as an imaging biomarker. NEOPLASIA. 2022 Jun;28. 100792. https://doi.org/10.1016/j.neo.2022.100792

Bibtex

@article{82f73b651b024a1699b5a104e316dd1b,
title = "In vivo imaging of microenvironmental and anti-PD-L1-mediated dynamics in cancer using S100A8/S100A9 as an imaging biomarker",
abstract = "PURPOSE: As a promotor of tumor invasion and tumor microenvironment (TME) formation, the protein complex S100A8/S100A9 is associated with poor prognosis. Our aim was to further evaluate its origin and regulatory effects, and to establish an imaging biomarker for TME activity.METHODS: S100A9-/-cells (ko) were created from syngeneic murine breast cancer 4T1 (high malignancy) and 67NR (low malignancy) wildtype (wt) cell lines and implanted into either female BALB/c wildtype or S100A9-/- mice (n = 10 each). Anti-S100A9-Cy5.5-targeted fluorescence reflectance imaging was performed at 0 h and 24 h after injection. Potential early changes of S100A9-presence under immune checkpoint inhibition (anti-PD-L1, n = 7 vs. rat IgG2b as isotype control, n = 3) were evaluated.RESULTS: In S100A9-/-mice contrast-to-noise-ratios were significantly reduced for wt and S100A9-/-tumors. No significant differences were detected for 4T1 ko and 67NR ko cells as compared to wildtype cells. Under anti-PD-L1 treatment S100A9 presence significantly decreased compared with the control group.CONCLUSION: Our results confirm a secretion of S100A8/S100A9 by the TME, while tumor cells do not apparently release the protein. Under immune checkpoint inhibition S100A9-imaging reports an early decrease of TME activity. Therefore, S100A9-specific imaging may serve as an imaging biomarker for TME formation and activity.",
keywords = "Animals, Biomarkers, Breast Neoplasms/metabolism, Calgranulin A/genetics, Calgranulin B/genetics, Female, Humans, Immune Checkpoint Inhibitors, Mice, Rats, Tumor Microenvironment",
author = "Anne Helfen and Jan Rie{\ss} and Olesja Fehler and Miriam St{\"o}lting and Zhengwen An and Vanessa Kocman and Annika Schnepel and Christiane Geyer and Mirjam Gerwing and Max Masthoff and Thomas Vogl and Carsten H{\"o}ltke and Johannes Roth and Tony Ng and Moritz Wildgruber and Michel Eisenbl{\"a}tter",
note = "Copyright {\textcopyright} 2022. Published by Elsevier Inc.",
year = "2022",
month = jun,
doi = "10.1016/j.neo.2022.100792",
language = "English",
volume = "28",
journal = "NEOPLASIA",
issn = "1476-5586",
publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - In vivo imaging of microenvironmental and anti-PD-L1-mediated dynamics in cancer using S100A8/S100A9 as an imaging biomarker

AU - Helfen, Anne

AU - Rieß, Jan

AU - Fehler, Olesja

AU - Stölting, Miriam

AU - An, Zhengwen

AU - Kocman, Vanessa

AU - Schnepel, Annika

AU - Geyer, Christiane

AU - Gerwing, Mirjam

AU - Masthoff, Max

AU - Vogl, Thomas

AU - Höltke, Carsten

AU - Roth, Johannes

AU - Ng, Tony

AU - Wildgruber, Moritz

AU - Eisenblätter, Michel

N1 - Copyright © 2022. Published by Elsevier Inc.

PY - 2022/6

Y1 - 2022/6

N2 - PURPOSE: As a promotor of tumor invasion and tumor microenvironment (TME) formation, the protein complex S100A8/S100A9 is associated with poor prognosis. Our aim was to further evaluate its origin and regulatory effects, and to establish an imaging biomarker for TME activity.METHODS: S100A9-/-cells (ko) were created from syngeneic murine breast cancer 4T1 (high malignancy) and 67NR (low malignancy) wildtype (wt) cell lines and implanted into either female BALB/c wildtype or S100A9-/- mice (n = 10 each). Anti-S100A9-Cy5.5-targeted fluorescence reflectance imaging was performed at 0 h and 24 h after injection. Potential early changes of S100A9-presence under immune checkpoint inhibition (anti-PD-L1, n = 7 vs. rat IgG2b as isotype control, n = 3) were evaluated.RESULTS: In S100A9-/-mice contrast-to-noise-ratios were significantly reduced for wt and S100A9-/-tumors. No significant differences were detected for 4T1 ko and 67NR ko cells as compared to wildtype cells. Under anti-PD-L1 treatment S100A9 presence significantly decreased compared with the control group.CONCLUSION: Our results confirm a secretion of S100A8/S100A9 by the TME, while tumor cells do not apparently release the protein. Under immune checkpoint inhibition S100A9-imaging reports an early decrease of TME activity. Therefore, S100A9-specific imaging may serve as an imaging biomarker for TME formation and activity.

AB - PURPOSE: As a promotor of tumor invasion and tumor microenvironment (TME) formation, the protein complex S100A8/S100A9 is associated with poor prognosis. Our aim was to further evaluate its origin and regulatory effects, and to establish an imaging biomarker for TME activity.METHODS: S100A9-/-cells (ko) were created from syngeneic murine breast cancer 4T1 (high malignancy) and 67NR (low malignancy) wildtype (wt) cell lines and implanted into either female BALB/c wildtype or S100A9-/- mice (n = 10 each). Anti-S100A9-Cy5.5-targeted fluorescence reflectance imaging was performed at 0 h and 24 h after injection. Potential early changes of S100A9-presence under immune checkpoint inhibition (anti-PD-L1, n = 7 vs. rat IgG2b as isotype control, n = 3) were evaluated.RESULTS: In S100A9-/-mice contrast-to-noise-ratios were significantly reduced for wt and S100A9-/-tumors. No significant differences were detected for 4T1 ko and 67NR ko cells as compared to wildtype cells. Under anti-PD-L1 treatment S100A9 presence significantly decreased compared with the control group.CONCLUSION: Our results confirm a secretion of S100A8/S100A9 by the TME, while tumor cells do not apparently release the protein. Under immune checkpoint inhibition S100A9-imaging reports an early decrease of TME activity. Therefore, S100A9-specific imaging may serve as an imaging biomarker for TME formation and activity.

KW - Animals

KW - Biomarkers

KW - Breast Neoplasms/metabolism

KW - Calgranulin A/genetics

KW - Calgranulin B/genetics

KW - Female

KW - Humans

KW - Immune Checkpoint Inhibitors

KW - Mice

KW - Rats

KW - Tumor Microenvironment

U2 - 10.1016/j.neo.2022.100792

DO - 10.1016/j.neo.2022.100792

M3 - SCORING: Journal article

C2 - 35367789

VL - 28

JO - NEOPLASIA

JF - NEOPLASIA

SN - 1476-5586

M1 - 100792

ER -